REVIEW Azelnidipine is a dihydropyridine calcium channel blocker with selectivity for L-type calcium channels that is approved in Japan for the treatment of patients with hypertension. It has a gradual onset and has a long-lasting hypotensive effect, with little increase in heart rate. Azelnidipine is approved for use in treating ischemic heart disease and cardiac remodeling after myocardial infarction. Azelnidipine has also been shown to have antioxidant effects in endothelial cells and cardiomyocytes.
Oizumi K, Nishino H, Koike H, Sada T, Miyamoto M, Kimura, Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker, Jpn. J. Pharmacol. 1989, 51 (1): 57-64.
Arita M, Hashizume T, Tanigawa K, Yamamoto H, Nishio I. A new Ca-antagonist, azelnidipine, reduced blood pressure during exercise without augmentation of sympathetic nervous system in essential hypertension: a randomized, double-blind, placebo-controlled trial. J Cardiovasc Pharmacol. 1999 Feb;33(2):186-92.
These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise. They are not sold to individuals. Additional restrictions may apply.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information.